Venous thromboembolism, encompassing deep vein thrombosis and pulmonary embolism,
is the third most common cause of vascular death after myocardial infarction and stroke …

Anticoagulant drugs have an essential role in the prevention and treatment of
thromboembolic diseases. Currently available anticoagulants substantially reduce the …

One of the main innovation emerged in recent years in the field of venous thromboembolism
(VTE) has been represented by the clinical development and marketing of new oral …

Anticoagulation therapy is mandatory in patients with pulmonary embolism to prevent
significant morbidity and mortality. The mainstay of therapy has been vitamin‐K antagonist …

For years, prevention and treatment of thromboembolic events have been restricted to the
use of heparins and vitamin K antagonists. These treatments, in spite of their unquestioned …

Venous thromboembolism (VTE) encompasses deep vein thrombosis and pulmonary
embolism and is a major health burden, both medically and economically. Anticoagulation is …

Thromboembolic disorders are among the major causes of morbidity and mortality, and
anticoagulation remains the cornerstone of prevention and treatment of these disorders …

Anticoagulants are recommended for the prevention and treatment of venous
thromboembolism (VTE). The new anticoagulants which target specific factors in the …

Traditional therapeutic oral anticoagulation strategies often require invasive dosing or
monitoring. Vitamin K antagonists (VKAs) have a large number of interactions, delayed …

Anticoagulant therapy is the cornerstone of treatment of venous thromboembolism (VTE).
The treatment needs rapid initial anticoagulaton to minimize the risk of thrombus extension …